Clinical Practice of Adalimumab and Infliximab Biosimilar Treatment in Adult Patients With Crohn's Disease (vol 27, pg 106, 2021)

被引：0
|
作者：
Daneses, Silvio [1 ,2 ,3 ]
机构：
[1] Humanitas Clin & Res Ctr IRCCS, Dept Gastroenterol, IBD Ctr, Rozzano, Italy
[2] Humanitas Univ, Dept Biomed Sci, Milan, Italy
[3] Humanitas Clin & Res Ctr, Dept Gastroenterol, IBD Ctr, Milan, Italy
来源：
JOURNAL OF ANIMAL SCIENCE | 2022年 / 100卷 / 09期
关键词：
D O I：
暂无
中图分类号：
S8 [畜牧、 动物医学、狩猎、蚕、蜂];
学科分类号：
0905 ;
摘要：
引用
收藏
页码：1367 / 1367
页数：1
相关论文
共 50 条
  • [1] Clinical Practice of Adalimumab and Infliximab Biosimilar Treatment in Adult Patients With Crohn's Disease (vol 27, pg 1367, 2021)
    Reinisch, Walter
    Gecse, Krisztina
    Halfvarson, Jonas
    Irving, Peter M.
    Jahnsen, Jorgen
    Peyrin-Biroulet, Laurent
    Rogler, Gerhard
    Schreiber, Stefan
    Danese, Silvio
    INFLAMMATORY BOWEL DISEASES, 2021, 27 (08) : 1367 - 1367
  • [2] Clinical Practice of Adalimumab and Infliximab Biosimilar Treatment in Adult Patients With Crohn's Disease
    Reinisch, Walter
    Gecse, Krisztina
    Halfvarson, Jonas
    Irving, Peter M.
    Jahnsen, Jorgen
    Peyrin-Biroulet, Laurent
    Rogler, Gerhard
    Schreiber, Stefan
    Danese, Silvio
    INFLAMMATORY BOWEL DISEASES, 2021, 27 (01) : 106 - 122
  • [3] Letter: are infliximab and adalimumab similar for Crohn's disease in clinical practice?
    Tursi, A.
    Elisei, W.
    Picchio, M.
    Penna, A.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2013, 37 (07) : 763 - 764
  • [4] Safety and efficacy of infliximab biosimilar (Remsima©) in Crohn's disease patients in clinical practice: results after 6 months of treatment
    Guerra Veloz, M. F.
    Arguelles Arias, F.
    Perea Amarillo, R.
    Castro Laria, L.
    Maldonado Perez, M. B.
    Benitez Roldan, A.
    Merino, V.
    Ramirez, G.
    Vilches Arenas, A.
    Caunedo Alvarez, A.
    JOURNAL OF CROHNS & COLITIS, 2016, 10 : S328 - S329
  • [5] INFLIXIMAB VERSUS ADALIMUMAB IN THE TREATMENT OF PERIANAL CROHN'S DISEASE
    Maas, Laura A.
    Limketkai, Berkeley N.
    Lazarev, Mark
    Melia, Joanna
    Selaru, Florin M.
    Parian, Alyssa M.
    GASTROENTEROLOGY, 2022, 162 (07) : S817 - S817
  • [6] Efficacy of adalimumab in patients with Crohn's disease and failure to infliximab therapy: a clinical series
    Cordero Ruiz, Patricia
    Castro Marquez, Cristina
    Mendez Rufian, Vanesa
    Castro Laria, Luisa
    Caunedo Alvarez, Angel
    Romero Vazquez, Javier
    Herrerias Gutierrez, Juan Manuel
    REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS, 2011, 103 (06) : 294 - 298
  • [7] Efficacy, tolerability, and safety of infliximab biosimilar in comparison to originator biologic and adalimumab in patients with Crohn disease
    Kaniewska, Magdalena
    Rosolowski, Mariusz
    Rydzewska, Grazyna
    POLISH ARCHIVES OF INTERNAL MEDICINE-POLSKIE ARCHIWUM MEDYCYNY WEWNETRZNEJ, 2019, 129 (7-8): : 484 - 489
  • [8] Adalimumab biosimilar comparable to originator in patients with advanced Crohn’s disease
    Ray K.
    Nature Reviews Gastroenterology & Hepatology, 2021, 18 (10) : 676 - 676
  • [9] Adalimumab or infliximab as monotherapy, or in combination with an immunomodulator, in the treatment of Crohn's disease
    Cosnes, J.
    Sokol, H.
    Bourrier, A.
    Nion-Larmurier, I.
    Wisniewski, A.
    Landman, C.
    Marteau, P.
    Beaugerie, L.
    Perez, K.
    Seksik, P.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2016, 44 (10) : 1102 - 1113
  • [10] Successful treatment with adalimumab in infliximab-resistant Crohn's disease
    Barthel, HR
    Gille, T
    Halbsguth, A
    Kramer, M
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2005, 20 (09) : 1464 - 1465
12345